Infliximab has also been shown to significantly increase hospitalization and mortality in patients with congestive heart failure.[85] IL-17A inhibitors may stabilize coronary atheromatous plaques in patients with coronary heart disease by controlling inflammation.[86, 87, 88] It is recommended to prefer IL-17A inhibitors over TNF inhibitors for SpA patients with congestive heart failure. Here, IL17A is linked to coronary artery disorder.